Structure Therapeutics Statistics
Total Valuation
GPCR has a market cap or net worth of $1.55 billion. The enterprise value is $316.42 million.
| Market Cap | 1.55B |
| Enterprise Value | 316.42M |
Important Dates
The last earnings date was Monday, November 9, 2026, after market close.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GPCR has 71.31 million shares outstanding. The number of shares has increased by 21.95% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 71.31M |
| Shares Change (YoY) | +21.95% |
| Shares Change (QoQ) | +0.29% |
| Owned by Insiders (%) | 2.44% |
| Owned by Institutions (%) | 84.89% |
| Float | 55.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.27 |
| P/TBV Ratio | 1.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.91, with a Debt / Equity ratio of 0.01.
| Current Ratio | 11.91 |
| Quick Ratio | 11.58 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -29.51% and return on invested capital (ROIC) is -21.85%.
| Return on Equity (ROE) | -29.51% |
| Return on Assets (ROA) | -20.23% |
| Return on Invested Capital (ROIC) | -21.85% |
| Return on Capital Employed (ROCE) | -28.57% |
| Weighted Average Cost of Capital (WACC) | -2.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.05M |
| Employee Count | 281 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GPCR has paid $765,000 in taxes.
| Income Tax | 765,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.83% in the last 52 weeks. The beta is -1.20, so GPCR's price volatility has been lower than the market average.
| Beta (5Y) | -1.20 |
| 52-Week Price Change | -33.83% |
| 50-Day Moving Average | 29.52 |
| 200-Day Moving Average | 46.63 |
| Relative Strength Index (RSI) | 38.78 |
| Average Volume (20 Days) | 1,057,915 |
Short Selling Information
The latest short interest is 7.15 million, so 13.72% of the outstanding shares have been sold short.
| Short Interest | 7.15M |
| Short Previous Month | 7.54M |
| Short % of Shares Out | 13.72% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.76 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -350.60M |
| Pretax Income | -293.12M |
| Net Income | -293.88M |
| EBITDA | -348.69M |
| EBIT | -350.60M |
| Earnings Per Share (EPS) | -$4.19 |
Balance Sheet
The company has $1.24 billion in cash and $6.83 million in debt, with a net cash position of $1.23 billion or $17.29 per share.
| Cash & Cash Equivalents | 1.24B |
| Total Debt | 6.83M |
| Net Cash | 1.23B |
| Net Cash Per Share | $17.29 |
| Equity (Book Value) | 1.22B |
| Book Value Per Share | 17.12 |
| Working Capital | 1.17B |
Cash Flow
In the last 12 months, operating cash flow was -$271.00 million and capital expenditures -$6.28 million, giving a free cash flow of -$277.28 million.
| Operating Cash Flow | -271.00M |
| Capital Expenditures | -6.28M |
| Depreciation & Amortization | 1.91M |
| Net Borrowing | n/a |
| Free Cash Flow | -277.28M |
| FCF Per Share | -$3.89 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GPCR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -21.95% |
| Shareholder Yield | -21.95% |
| Earnings Yield | -19.28% |
| FCF Yield | -17.89% |
Analyst Forecast
The average price target for GPCR is $104.31, which is 380.03% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $104.31 |
| Price Target Difference | 380.03% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |